🏛️ Verified NIH Record • Updated 2026-08-13

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) (NCT06843447)

A Phase 1b/2 Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan With or Without Other Anticancer Investigational Agents in Participants With High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Have Relapsed After Prior Platinum-based Chemotherapy

🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: Merck Sharp & Dohme LLC

🩺 Plain-English Summary (8th-Grade Level)

Researchers are looking for other ways to treat relapsed high-grade serous ovarian cancer. Relapsed means the cancer came back after treatment. High-grade means the cancer cells grow and spread quickly. Serous means the cancer started in the cells that cover the ovaries, the lining of the belly, or in the fallopian tubes. Standard treatment (usual treatment) for people with relapsed high-grade serous ovarian cancer may include: * Chemotherapy, which is a treatment that uses medicine to destroy cancer cells or stop them from growing * Targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread Raludotatug deruxtecan (R-DXd) is a study treatment that is an antibody drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. Researchers want to know if R-DXd is safe to take with other treatments and if people tolerate them together. They also want to learn how many people have the cancer respond (gets smaller or goes away) to the treatments.

Who can join: Review the eligibility criteria below.

Location: Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0019) — New Haven, Connecticut

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (30 Sites)

Showing the first 25 of 30 sites.

  • Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0019) — New Haven, Connecticut
  • The University of Louisville, James Graham Brown Cancer Center ( Site 0009) — Louisville, Kentucky
  • TRIALS 365 ( Site 0020) — Shreveport, Louisiana
  • Dana-Farber Cancer Institute ( Site 0015) — Boston, Massachusetts
  • Memorial Sloan Kettering Cancer Center ( Site 0003) — New York, New York
  • OU Health University of Oklahoma Medical Center ( Site 7000) — Oklahoma City, Oklahoma
  • Texas Oncology - DFW ( Site 8000) — Fort Worth, Texas
  • Houston Methodist Hospital ( Site 0010) — Houston, Texas
  • START Mountain Region ( Site 0008) — West Valley City, Utah
  • University of Virginia Health System ( Site 0011) — Charlottesville, Virginia
  • Centre Hospitalier de l'Université de Montréal ( Site 0102) — Montreal, Quebec
  • McGill University Health Centre ( Site 0100) — Montreal, Quebec
  • Rambam Health Care Campus ( Site 0202) — Haifa,
  • Shaare Zedek Medical Center ( Site 0201) — Jerusalem,
  • Rabin Medical Center ( Site 0203) — Petah Tikva,
  • Sheba Medical Center ( Site 0200) — Ramat Gan,
  • Institut Català d'Oncologia - L'Hospitalet ( Site 0302) — L'Hospitalet de Llobregat, Barcelona
  • HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA ( Site 0307) — Majadhonda, Madrid
  • Clinica Universidad de Navarra ( Site 0301) — Madrid, Madrid, Comunidad de
  • Hospital General Universitario de Valencia ( Site 0305) — Valencia, Valenciana, Comunitat
  • Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0300) — Barcelona,
  • Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD ( Site 0303) — Madrid,
  • Hospital Universitario 12 de Octubre ( Site 0304) — Madrid,
  • Hospital Universitario Virgen de la Victoria ( Site 0306) — Málaga,
  • University Hospitals Sussex NHS Foundation Trust ( Site 0404) — Brighton, East Sussex

📞 Contact the Study Coordinator

Phone: (888) 577-8839

Email: Trialsites@msd.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Ovarian Cancer Recurrent

Explore by condition: All Ovarian Cancer Recurrent clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗